No disclosed relationships extracted for ENLVyet. The EDGAR pass hasn't reached this filing; the graph grows as filings are read.
Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. It is developing Allocetra, an off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state. Resetting non-homeostatic macrophages into homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. Diseases, such as solid cancers, sepsis, COVID-19, and others reprogram macrophages out of homeostatic state. Its Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents. The company has a research collaboration with Yale Cancer Center for the assessment of Allocetra to enhance the activity of checkpoint inhibitors in solid tumors. Enlivex Therapeutics Ltd. was incorporated in 2005 and is headquartered in Nes Ziona, Israel.
No earnings record for ENLV on the current feed.
Nothing on the wire mentions ENLV yet. Iris sweeps the public feeds every quarter hour; headlines land here the moment a sweep tags them.
How ENLV has moved on past release days vs its typical ±3.7% day, and how often it closed up. Computed from daily closes — not a forecast.